Cellectis S.A.
CLLS · Biological Products, (No Diagnostic Substances) · EDGAR filings ↗
Grade
D49Clinical-stage gene-editing biotech with deep losses and limited runway, partly de-risked by AstraZeneca backing and collaboration revenue.
Strengths
- Revenue up 76% on collaboration income; AstraZeneca strategic relationship and JRCA provide validation and funding optionality
- Cash $61.5M with ~5.9 quarters of runway
Risks
- Deep losses: net margin -93%, operating margin -45%, ROE -89%; binary clinical/regulatory risk across UCART pipeline
- Servier's CD19 discontinuation, manufacturing complexity and need to raise capital constrained by French law
Notable findings
- No interest coverageInterest coverage -0.65 (cannot cover interest)
- Net lossNet loss (net margin -92.7%)
- Cash burnNegative free cash flow (-41.8M)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-06-30 — PHASE1/PHASE2 · B-cell Acute Lymphoblastic Leukemia
Key metrics
Gross margin
100.0%
Operating margin
-45.3%
Net margin
-92.7%
Return on equity
-89.1%
Return on assets
-20.8%
Revenue growth (QoQ)
75.8%
Interest coverage
-0.6×
Free cash flow
-$42M
Tangible book value
$76M
Cash & investments
$62M
Cash runway
6q
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05607420 ↗ | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma B-cell Non-Hodgkin Lymphoma (B-NHL) | PHASE1/PHASE2 | Recruiting | 2027-08-01 |
| NCT04150497 ↗ | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) B-cell Acute Lymphoblastic Leukemia | PHASE1/PHASE2 | Recruiting | 2026-06-30 |
| NCT03190278 ↗ | Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia | PHASE1 | Active Not Recruiting | 2024-12-24 |
| NCT04142619 ↗ | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) Relapsed/Refractory Multiple Myeloma | PHASE1 | Terminated | 2023-06-18 |
| NCT04106076 ↗ | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia Acute Myeloid Leukaemia | PHASE1 | Withdrawn | 2019-12-05 |
| NCT03203369 ↗ | Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | PHASE1 | Terminated | 2019-06-27 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-20 | 2025-12-31 | 0001193125-26-116428 ↗ |
| 20-F | 2025-03-14 | 2024-12-31 | 0000950170-25-039038 ↗ |
| 20-F | 2024-04-29 | 2023-12-31 | 0000950170-24-050016 ↗ |
| 20-F | 2023-03-14 | 2022-12-31 | 0001193125-23-070116 ↗ |
| 20-F | 2022-03-03 | 2021-12-31 | 0001193125-22-064482 ↗ |
| 20-F | 2021-03-04 | 2020-12-31 | 0001193125-21-069635 ↗ |
| 20-F | 2020-03-05 | 2019-12-31 | 0001193125-20-061833 ↗ |
| 20-F | 2019-03-12 | 2018-12-31 | 0001193125-19-071189 ↗ |
| 20-F | 2018-03-13 | 2017-12-31 | 0001193125-18-080876 ↗ |
| 20-F | 2017-03-23 | 2016-12-31 | 0001193125-17-093898 ↗ |
| 20-F | 2016-03-21 | 2015-12-31 | 0001193125-16-512098 ↗ |